Navigation Links
Orexigen(R) Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk
Date:10/24/2009

>Contrave Obesity Research (COR) Trial Design and Safety Profile

All Phase 3 trials in the COR program were 56 week, randomized, double-blind, placebo-controlled trials. The co-primary endpoints were the proportion of patients achieving at least 5% weight loss and percent change in body weight compared to placebo. Secondary endpoints included multiple markers of cardiometabolic risk, patient reported food cravings and eating control measures, as well as HbA1c in the COR-Diabetes trial. Patients were randomized to receive either placebo or Contrave, BID, with a four week titration period.

As previously reported, seven serious adverse events were attributed by investigators as possibly related to Contrave treatment across the entire COR program. These include cholecystitis (gallbladder inflammation), seizure, palpitations, paresthesia and vertigo. The most frequently observed treatment-emergent adverse events were nausea, constipation and headache. Nausea was the leading adverse event resulting in discontinuation; however, for the majority of patients experiencing nausea, it was mild to moderate, transient and manageable.

At week 56, mean blood pressure was generally unchanged from baseline for Contrave patients compared to placebo patients, who tended to experience a slight decrease (approximately 2 mm Hg) from baseline. Contrave treatment did not appear to disrupt the normal circadian pattern of blood pressure. There was a slight increase in pulse (approximately 1 beat per minute) in Contrave patients compared to placebo patients, whose pulse was generally unchanged. There were no meaningful treatment effects on ECGs or laboratory measures including liver function tests. Treatment with Contrave was not associated with increases in symptoms of depression or suicidal ideation.

The Company is on track to submit a New Drug Application (NDA) for Contr
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
2. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
3. Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors
4. Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer
5. Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R)
6. Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock
7. Orexigen(R) Therapeutics Prices Public Offering of Common Stock
8. Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results
9. Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients
10. Prime Therapeutics Receives TIPPS Certification
11. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... (PRWEB) May 24, 2013 A recent study ... of America dreads the upcoming bathing suit season. Almost 138 ... the weather heats up due to weight issues and a ... mercury rises. PharmaCo Labs recommends that those anxious about ... PhenObestin 37.5 as part of an overall effort to improve ...
(Date:5/24/2013)... myMEDholiday.com, a popular medical tourism portal which ... important medical travel destinations in Asia, has added a ... ensure a safe and successful trip for anyone planning ... tips on cost-savings, how to find the appropriate doctors ... wealth other essential advice. , A top-level marketing representative ...
(Date:5/24/2013)... Range Kleen Mfg. strives to “TCOTC.” Our ... from the President's desk to the Shipping Dock.” We hold ... and having passion while creating excellence and quality being results ... to do the right thing and what better way to ... by devastation. , Throughout the year Range Kleen donates to ...
(Date:5/24/2013)... May 24, 2013 This week is ... and their efforts to provide the best emergency care ... of this week is also to educate the public ... of survival. Citizens are the first link, and a ... proper bystander CPR after a cardiac arrest can triple ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- Patients hospitalized for ... if they,re admitted on Mondays or in the morning, ... of stay are highest among heart failure patients admitted ... researchers, who are scheduled to present their findings Saturday ... Failure Association of the European Society of Cardiology. ...
Breaking Medicine News(10 mins):Health News:PhenObestin 37.5 Can Help Make Bathing Suit Season Less Stressful 2Health News:PhenObestin 37.5 Can Help Make Bathing Suit Season Less Stressful 3Health News:myMEDholiday.com Introduces International Patient Guide to Assist People Planning Treatment Abroad 2Health News:Range Kleen Partners with Berndes in Red Cross Promotion: Taking Care of Oklahoma 2Health News:Acadian Medics Reunite with Miracle Baby 2Health News:Monday Best Time for Hospitalization With Heart Failure, Study Says 2
... ... expertise in turnarounds and improving hospital profitability joins StatCom in a strategic partnership program that ... ... addition of Tom Brunelle FACHE, MBA, to the StatCom team. Previously Brunelle served as EVP ...
... , , , , , , , , ... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SVA),a leading China ... of the acquisition of buildings and land use,rights. The total consideration ... ), which will be financed from working capital. The,initial payment of ...
... ... connectivity combo solution to accelerate time-to-market for handset manufacturers to deliver interoperable sport, ... ... 15, 2010 -- ANT Wireless, a division of Dynastream Innovations Inc. (ANT) and ...
... ... has become the company’s Vice President of Product Services. Among his responsibilities, Randy will ... Notification Network, White Pine’s flagship personal health record solution. , ... (PRWEB) February 14, 2010 -- White ...
... ... Robert Lukasik has joined the company as Vice President of Sales. Separately, Kardea ... , ... 2010 -- Kardea Nutrition ™ LLC announced today that Robert Lukasik has joined the ...
... issue of the Journal of Clinical Sleep Medicine ... (OSA) report a significantly lower frequency of nightmares than ... OSA suppresses the cognitive experience of nightmare recall. ... nightmare recall decreased linearly as sleep apnea severity increased. ...
Cached Medicine News:Health News:Tom Brunelle Joins StatCom as Enterprise VP, Northeast Region 2Health News:Tom Brunelle Joins StatCom as Enterprise VP, Northeast Region 3Health News:Sinovac Completes Acquisition Aimed at Expanding Production Capacity 2Health News:Sinovac Completes Acquisition Aimed at Expanding Production Capacity 3Health News:ANT+ and Texas Instruments connect proven ultra low power sensors to smartphones 2Health News:ANT+ and Texas Instruments connect proven ultra low power sensors to smartphones 3Health News:ANT+ and Texas Instruments connect proven ultra low power sensors to smartphones 4Health News:Longtime Quality Assurance Executive Randy Johnson Joins White Pine Systems as Vice President of Product Services 2Health News:Kardea Nutrition Adds V.P. Sales, Extends Distribution Network 2Health News:Severe sleep apnea decreases frequency of nightmare recall 2
(Date:5/24/2013)... In accordance with Rule 17.1 and Rule 2.9 of the ... Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") today announced ... Background On 2 May 2013, Echo ... entire of the issued and to be issued share capital ... On 20 May 2013, Royalty Pharma announced the terms ...
(Date:5/23/2013)... SHENYANG, CHINA , May 24, 2013 /PRNewswire/ ... ("3SBio" or the "Company"), a leading ... developing, manufacturing and marketing biopharmaceutical products, announced today ... (the "EGM"), the Company,s shareholders voted in favor ... previously announced agreement and plan of merger dated ...
(Date:5/23/2013)... -- Amgen (NASDAQ: AMGN ) will present at ... Thursday, May 30, 2013, at the Westin Boston Waterfront Hotel, ... Daylight Time. Arvind Sood , vice president ... Live audio of the presentation can be accessed from the ... A replay of the webcast will also be available on ...
Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 93SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
... VIEW, Calif., Dec. 12, 2011  IRIDEX Corporation (Nasdaq: ... clinical study(1) compiled over 10 years demonstrates the safety ... macular edema (DME) without the retina tissue damage associated ... Centers for Disease Control and Prevention, DME, a swelling ...
... Mylan Inc. (Nasdaq: MYL ) today announced ... Pharma, L.P., Mylan,s fully integrated specialty pharmaceutical business. ... professional experience in strategic product launches, marketing, commercialization, sales ... president and chief executive officer of MiddleBrook Pharmaceuticals. In ...
Cached Medicine Technology:10-Year Study Demonstrates IRIDEX MicroPulse™ Laser Therapy Safe, Effective for Patients with Diabetic Macular Edema 210-Year Study Demonstrates IRIDEX MicroPulse™ Laser Therapy Safe, Effective for Patients with Diabetic Macular Edema 3Mylan Names John Thievon President of Dey Pharma 2
... This antimicrobial skin cleanser will not leave ... with frequent washings. With persistent Antimicrobial action, ... of microorganisms, including gram-negative and gram-positive bacteria, ... as a 15 second hand wash. The ...
... Prep Pads prepares the skin for improved ... dry, it leaves a thin film on ... surface and a barrier for natural body ... a dressing or tape. Skin Protectant is ...
... Povidone Iodine Prep Pads ... surface pathogens including bacteria, ... yeast. Povidone Iodine is ... wounds or mucus membranes. ...
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th...
Medicine Products: